Supplementary Table S2 from FDA Approval Summary: Ivosidenib in Combination with Azacitidine for Treatment of Patients with Newly Diagnosed Acute Myeloid Leukemia with an <i>IDH1</i> Mutation
crossref(2024)
摘要
Frequent Laboratory Abnormalities
查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要